A proposed probe of pharmacy benefit managers (PBMs) by the Federal Trade Commission did not win enough votes to go forward; California exits the crisis phase of the pandemic; Abbott infant formula has been recalled after 1 death.
With a vote that failed to reach a consensus, the Federal Trade Commission (FTC) halted a probe into whether reimbursement rates set by pharmacy benefit managers (PBMs) unfairly favor affiliated pharmacies at the expense of independent or specialty ones, Bloomberg Law reports. PBMs manage prescription drug benefits for health insurers and Medicare Part D plans, and have traditionally lacked strong federal oversight. The 2-to-2 vote was along party lines with Republican commissioners voting against, claiming the study’s plans do not adequately call for measuring how these middlemen could influence out-of-pocket costs.
California has become the first state to adopt an endemic virus policy against COVID-19, which includes emphasizing prevention and quickly responding to outbreaks as opposed to mandated masking and business shutdowns, according to The Associated Press. The plan was introduced by Governor Gavin Newsom (D) yesterday, who said the state was moving past the crisis phase of the pandemic and into a phase of living with the virus. By definition, a virus becomes endemic when it exists in a community but becomes manageable as immunity builds. The state’s emergency orders will not be immediately lifted, however.
The FDA has warned parents not to use 3 powdered infant formulas manufactured by an Abbott plant in Michigan as they have been tied with bacterial contamination, The Associated Press reports. Four infants have been hospitalized after injesting the formula, one of whom died. One reported case involved salmonella and the other 3 Cronobacter sakazakiim—a rare germ linked with blood infections. Abbott is recalling all potentially impacted formulas, which include certain lots of Similac, Alimentum, and EleCare with expiration dates of April 1, 2022, or later. The FDA is also inspecting the company’s Michigan plant.
Health Equity & Access Weekly Roundup: November 2, 2024
November 2nd 2024This week’s Center on Health Equity & Access highlights emphasize the role of social determinants of health in policy-making and underscore the importance of addressing rising costs and challenges employers face.
Read More
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen
Double Trouble: High-Deductible Plans Raise Maternity Care Costs Across 2 Calendar Years
June 27th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the June 2024 issue of The American Journal of Managed Care® about how annual high-deductible insurance plans increase maternity care costs when pregnancies cross 2 calendar years.
Listen
Overhauling Quality Measurement in the US: Measure What Matters
October 30th 2024As the US charts its course through the next political era, it is crucial that we boldly allocate resources and prioritize what truly impacts patients. When faced with complexity, feasibility concerns, or entrenched norms, we must proclaim: “It’s the outcomes, stupid.”
Read More